GLUT1 Deficiency Syndrome and Epilepsy

Glucose transporter type 1 deficiency syndrome — usually shortened to GLUT1 deficiency syndrome or Glut1DS — is a rare, treatable neurometabolic disorder in which the brain does not receive enough glucose across the blood–brain barrier. Epilepsy is common, but it is only one part of a broader neurological spectrum that can also include movement disorders, developmental difficulties, speech problems and exercise- or fasting-related symptoms.

Most confirmed cases are caused by pathogenic variants in SLC2A1, the gene that encodes the GLUT1 glucose transporter. The disorder is therefore both genetic and metabolic: the genetic change disrupts a metabolic fuel pathway used by the brain.

What GLUT1 normally does

Glucose is one of the brain’s major energy fuels. It cannot simply diffuse freely from the bloodstream into brain tissue. Transport proteins are required to move it across the blood–brain barrier.

GLUT1 is the main transporter responsible for carrying glucose across that barrier. When GLUT1 function is reduced, the brain can be relatively deprived of glucose even when the glucose concentration in the bloodstream is normal. This is why Glut1DS is described as a brain energy failure syndrome.

Why seizures occur

Neurons require a continuous energy supply to maintain ion gradients, release neurotransmitters and regulate electrical activity. When glucose delivery to the brain is chronically inadequate, neuronal networks can become dysfunctional and seizures can develop.

The mechanism is more complex than one simple “low-energy seizure pathway”, and the clinical severity varies widely. Some people have early and frequent seizures with developmental impairment, while others have milder phenotypes dominated by movement symptoms, intermittent episodes or epilepsy that is recognised later.

What can Glut1DS look like?

International consensus recommendations identify several features that can raise suspicion, including:

seizures, often beginning in infancy or childhood
unusual eye–head movements in infancy
developmental delay or intellectual disability
speech and language difficulties
slowing of head growth in some children
movement disorders such as dystonia, ataxia or chorea
episodes triggered or worsened by fasting, exertion or prolonged activity in some people

No single feature is present in every person. The recognised phenotype has broadened substantially since the disorder was first described, and milder cases can present later in childhood, adolescence or adulthood.

The seizure pattern is variable

Glut1DS is not associated with only one seizure type. Generalised and focal seizure types have both been reported, and some people can present with absence seizures or other epilepsy phenotypes.

Seizures may become less prominent with age in some people while movement symptoms become more noticeable. That age-related change can make the underlying disorder easier to miss if clinicians focus only on current seizure frequency.

The key laboratory clue: low CSF glucose with normal blood glucose

One of the most important diagnostic findings is hypoglycorrhachia — an abnormally low glucose concentration in cerebrospinal fluid (CSF) despite a normal blood glucose concentration.

GeneReviews notes that in more severe phenotypes CSF glucose is often below 40 mg/dL with a low CSF-to-blood glucose ratio, but the ranges overlap and milder Glut1DS can have higher values. These figures therefore support diagnosis rather than acting as a universal pass-or-fail threshold.

A paired blood glucose sample is important because CSF glucose has to be interpreted in relation to blood glucose. Specialist protocols may also specify fasting time and timing of the blood sample before lumbar puncture.

Genetic testing

Pathogenic variants in SLC2A1 confirm many cases. Genetic testing may be performed through a targeted epilepsy or movement-disorder panel, exome or genome sequencing, or another genomic pathway depending on the health system.

A negative genetic test does not automatically exclude the diagnosis if the biochemical and clinical evidence remains strongly suggestive. Specialist interpretation is needed, especially for variants of uncertain significance.

EEG and MRI

EEG findings can vary with age and seizure type. EEG can support epilepsy classification and may show changes related to fasting or feeding in some people, but it does not diagnose Glut1DS by itself.

Brain MRI may be normal or show non-specific findings. A normal MRI therefore does not rule out Glut1DS, because the central problem is glucose transport and brain energy supply rather than necessarily a visible structural lesion.

Why ketogenic dietary therapy is different here

Ketogenic dietary therapies are a disease-specific treatment for Glut1DS. They produce ketone bodies, which can cross into the brain through transport systems that do not depend on GLUT1. The brain can then use ketones as an alternative fuel.

International consensus guidance considers ketogenic dietary therapy a standard treatment for Glut1DS. This is different from using a ketogenic diet simply as another antiseizure treatment in drug-resistant epilepsy: in Glut1DS it directly addresses the brain’s fuel shortage.

The exact dietary approach, fat-to-carbohydrate ratio, calorie and protein provision, supplements, monitoring and duration must be individualised by an experienced ketogenic-diet team. Children and adults should not attempt a therapeutic ketogenic diet without specialist supervision.

How effective is ketogenic dietary therapy?

A systematic review of published Glut1DS cases found improvement in epilepsy in a large majority of treated patients, with benefits also reported for movement symptoms and cognition. Outcomes varied, but earlier treatment was generally associated with better results.

That does not mean every symptom disappears. Developmental, cognitive or movement difficulties can persist, particularly when diagnosis and treatment occur after years of reduced brain glucose availability.

What role do antiseizure medicines have?

Antiseizure medicines may be used, particularly before the metabolic diagnosis is recognised or when seizures persist despite dietary treatment. However, conventional antiseizure medicines do not correct the underlying glucose-transport defect.

This is one reason international experts emphasise early diagnosis. A person can appear to be receiving appropriate epilepsy treatment while the brain’s energy deficit remains untreated.

Movement disorders and exercise-related symptoms

Glut1DS can cause dystonia, ataxia, spasticity, chorea or episodic movement problems. In some people, symptoms become more noticeable after prolonged exercise, fasting or missed meals.

Paroxysmal exercise-induced dyskinesia can be an important clue, particularly when it occurs alongside epilepsy, developmental differences or a family history compatible with an SLC2A1-related disorder.

Glut1DS across the lifespan

The phenotype can change with age. Seizures may lessen in later childhood, adolescence or adulthood in some people, while movement disorders, speech difficulty, fatigue, coordination problems or exercise-related symptoms remain significant.

Adults with unexplained movement disorders or a history of childhood epilepsy may therefore still be diagnosed with Glut1DS, especially when earlier testing was limited or the phenotype was considered too mild for the classic description.

Inheritance and family testing

SLC2A1-related Glut1DS is usually inherited in an autosomal dominant manner, although many affected people have a new variant that was not present in either parent. Less commonly, other inheritance patterns and mosaicism can complicate family risk.

Genetic counselling can explain recurrence risk, the meaning of a new versus inherited variant, and whether relatives should be offered testing.

Worldwide access

Diagnosing and treating Glut1DS requires more than recognising seizures. Access may depend on lumbar puncture and specialist CSF analysis, genetic testing, metabolic expertise and a ketogenic-diet service able to provide long-term dietetic monitoring.

Those resources are not equally available worldwide. In settings with limited genetic testing or specialist dietetic services, people with Glut1DS may remain labelled as having unexplained or drug-resistant epilepsy for years. Cost and availability of suitable foods, formulas, supplements and laboratory monitoring can also affect whether ketogenic therapy is sustainable.

The central point

Glut1DS is not simply epilepsy plus low blood sugar. It is a disorder of glucose transport into the brain. Blood glucose may be normal while the brain is under-fuelled. That distinction matters because ketogenic dietary therapy can provide an alternative brain fuel and directly target the metabolic problem.

Sources

Medical note: therapeutic ketogenic diets require specialist medical and dietetic supervision. They can cause nutritional, gastrointestinal, metabolic and other complications if used inappropriately.

Evidence checked: September 2026.